Patient-Specific Quality Assurance Using a 3D-Printed Chest Phantom for Intraoperative Radiotherapy in Breast Cancer

Yeonho Choi†, Ik Jae Lee†, Kwangwoo Park2, Kyung Ran Park3, Yeona Cho1, Jun Won Kim1 and Ho Lee1*

1 Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 2 Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, 3 Department of Radiation Oncology, Kosin University College of Medicine, Busan, South Korea

This study aims to confirm the usefulness of patient-specific quality assurance (PSQA) using three-dimensional (3D)-printed phantoms in ensuring the stability of IORT and the precision of the treatment administered. In this study, five patient-specific chest phantoms were fabricated using a 3D printer such that they were dosimetrically equivalent to the chests of actual patients in terms of organ density and shape around the given target, where a spherical applicator was inserted for breast IORT treatment via the INTRABEAM™ system. Models of lungs and soft tissue were fabricated by applying infill ratios corresponding to the mean Hounsfield unit (HU) values calculated from CT scans of the patients. The two models were then assembled into one. A 3D-printed water-equivalent phantom was also fabricated to verify the vendor-provided depth dose curve. Pieces of an EBT3 film were inserted into the 3D-printed customized phantoms to measure the doses. A 10 Gy prescription dose based on the surface of the spherical applicator was delivered and measured through EBT3 films parallel and perpendicular to the axis of the beam. The shapes of the phantoms, CT values, and absorbed doses were compared between the expected and printed ones. The morphological agreement among the five patient-specific 3D chest phantoms was assessed. The mean differences in terms of HU between the patients and the phantoms was 2.2 HU for soft tissue and −26.2 HU for the lungs. The dose irradiated on the surface of the spherical applicator yielded a percent error of −2.16% ± 3.91% between the measured and prescribed doses. In a depth dose comparison using a 3D-printed water phantom, the uncertainty in the measurements based on the EBT3 film decreased as the depth increased beyond 5 mm, and a good agreement in terms of the absolute dose was noted between the EBT3 film and the vendor data. These results demonstrate the applicability of the 3D-printed chest phantom for PSQA in breast IORT. This enhanced precision offers new opportunities for advancements in IORT.

Keywords: intraoperative radiation therapy (IORT), patient-specific quality assurance, 3D printing, INTRABEAM™, breast cancer
INTRODUCTION

Intraoperative radiation therapy (IORT) is a treatment modality that entails accelerated partial breast irradiation for early-stage breast cancer patients (1, 2). IORT generally refers to the direct delivery of a single-fraction dose of highly localized radiation to the periphery of the lumpectomy bed during surgery (3). Its major advantage is that it offers the direct visualization of the tumor bed without incurring the risk of a marginal miss. This helps minimize damage to the healthy tissue by reducing the volume and dose of radiation to the normal surrounding tissue (4). Furthermore, compared with conventional whole-breast irradiation (WBI) over 5 to 5.5 weeks followed by tumor-bed boost or hypofractionated WBI over 3 weeks with a boost, IORT is completed in one day, and intraoperative irradiation allows for the immediate treatment of the surgical bed in 30 min to avoid a delay between surgery and external beam radiotherapy. This is convenient for the patient and helps reduce cost. Treating a smaller volume of normal tissue instead of performing WBI enables the reduction of potential lung and cardiac toxicities arising from radiation treatment and enhances tumor control (5–7).

IORT requires specialized radiotherapy equipment. In this regard, INTRABEAM™ (Carl Zeiss Surgical GmbH, Oberkochen Germany) uses a low-energy (50 kV) X-ray generator to provide partial-breast irradiation (8). This system uses spherical applicators to deliver a uniform dose on the inner surface of the breast lumpectomy cavity and irradiates high-dose (10–20 Gy) beams at once. Therefore, it is essential to ensure safe and accurate delivery through a patient-specific quality assurance (PSQA) process that verifies that the treatment device is physically capable of delivering the expected dose distribution prior to patient treatment. Because the radiation dose cannot be measured directly in the patient, it is common to create phantoms that mimic human radiation characteristics. Patient-specific dose measurements are often performed using radiation therapy phantoms combined with various dosimeters. These phantoms are made of homogeneous materials that simulate representative organs. However, commercially available phantoms for IORT are not supported for clinical use. Moreover, because most IORT clinics do not have a treatment planning system (TPS), a thorough understanding of the dose distribution of IORT is essential for safe, effective, and efficient treatment delivery. Special attention needs to be paid to all aspects of the treatment for each patient. However, it is difficult to perform accurate predictions regarding IORT because the volume of the tumors removed may vary depending on the surgery outcome. Thus, pretreatment planning and PSQA are limited (9, 10).

There have been attempts to manufacture customized objects incorporating 3D printing technology into various applications of radiation therapy (11–17). In this manner, to overcome the limitations of IORT’s PSQA, we ensure the stability of IORT by creating a PSQA phantom via 3D printing. This study investigates the feasibility of verifying IORT dosimetry using a 3D-printed water-equivalent phantom as well as patient-specific 3D chest phantoms fabricated by simulating the actual structure of the body of the patient around the target. We explore the effectiveness of the 3D-printed phantoms fabricated by considering the infill ratio corresponding to the average HU value assigned to the patient’s CT. We also examine the qualification and quantification of the depth dose and the dose administered on the surface of the applicator to ensure that the delivered dose matches the expected dose.

MATERIALS AND METHODS

INTRABEAM™ System

The INTRABEAM™ system consists of a miniaturized accelerator (XRS) that accelerates electrons through a 10-cm drift tube, with a maximum voltage of 50 kV, onto a gold target where low-energy photons are produced and then emitted isotropically. An internal radiation monitor is used to detect the X-ray photons emitted in the direction of the cathode and record the dose output in real time. The miniaturized accelerator is inserted into the arm of the INTRABEAM carrier, which can be moved smoothly to any position in the operating room owing to the integral casters located at its base. Weight compensation and six axes provide sufficient freedom to place the miniaturized accelerator in any position in 3D space for access to the targeted area. Electromagnetic brakes hold the miniaturized accelerator in the exact set position during treatment. The operator can know the dose being delivered at any time throughout the treatment through the online dose monitoring data displayed on the treatment screen of the control terminal on the INTRABEAM cart. Spherical applicators are used for the intracavitary or intraoperative delivery of radiation to the tumor bed, e.g., during breast-conserving surgery. The applicator fills the cavity created by the excision of the tumor. The tissue on the tumor bed adheres to the applicator via surface tension. The probe tip is centered within the applicator and, therefore, at the tumor cavity. The INTRABEAM spherical applicators, which are reusable and sterilizable, are available in 5 mm increments, with diameters ranging from 15 mm to 50 mm. In this study, applicators with a diameter of 35 mm were used.

Absolute Dosimetry Using Zeiss Water Phantom

Zeiss supplies a special water phantom consisting of a 3D translational stage for precise source positioning and a PTW 34013 soft X-ray ionization chamber (18). To calculate the dosage rate in water for the XRS using this phantom, Eq. 1 is suggested in the user manual (19):

$$DR_{w}^{Zeiss} = M_{raw} \cdot P_{TP} \cdot N_{k} \cdot K_{Q} \cdot K_{c} \cdot D_{w}$$

(1)

where $N_{k}$ is the ion chamber calibration factor (Gy/nC), $M_{raw}$ is the ionization charge (C) collected in 60 s for a chamber located at depth $z$ in water, and $P_{TP}$ is the correction factor for room temperature (T) and pressure (P) at the time of dose measurement. The beam quality correction factor, $K_{Q}$, was set to unity ($K_{Q} = 1$) based on the fact that the T30 spectrum used as a reference X-ray beam, with $E_{eff} = 16.4$ kV and HVL = 0.43 mm Al, best matched the INTRABEAM spectrum (18). $K_{c}$ was the chamber conversion factor that converted air kerma measurements into doses in water for the chamber in the T30 spectrum.

Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 629927

Choi et al. Patient-Specific Quality Assurance for IORT
spectrum \( (K_{\text{Ko}} - D_{w} = 1.045) \). The manufacturer provided the calibration depth dose curve, where the measured \( D_{w}^{\text{Zeiss}} \) was plotted as a function of depth \( z \).

**Fabrication of 3D-Printed Customized Phantom**

**Figure 1** illustrates the schematic design of the customized chest phantom fabricated by the 3D printer. CT image data for each patient, in the digital imaging and communications in medicine file format, were used to create a virtual 3D-printed chest phantom. A CT slice was collected every 3 mm and reconstructed as a 1-mm-spaced slice. Modifications to the CT images were performed using the MIM Maestro software (version 6.1, MIM Software Inc., USA). The growth in the seed region, followed by a manually adjusted 2D brush, was used to select the region of interest (ROI) that covered one side of the lung close to the tumor and the ROI that corresponded to the soft tissue including the breast. The mean HU values of voxels in each ROI were calculated.

3D Slicer was used to define the initial virtual object to form the 3D chest phantom based on the patient’s CT data. The virtual object with surface information in terms of triangular meshes was stored in the stereolithography (STL) file format, and it could be read by the 3D printer software. Using Blender, the converted raw 3D object was refined by disregarding any defective meshes using the built-in “shrink-wrap” function. In addition, we prepared a spherical applicator space by considering the size of the tumor to be removed from the site where the IORT applicator would be inserted. It was also formed in four parts so that pieces of the EBT3 film could be placed horizontally and vertically between parts.

Based on this new surface, the 3D-printable customized chest phantom was fabricated using a fused deposition-modeling (FDM) 3D printer (DP200; 3D WOX, Sindoh, South Korea) that employed a polylactic acid (PLA) filament with a physical density \( (\rho) \) of 1.25 g/cm\(^3\). The printing parameters comprised a speed of 20 mm/s and layer thickness of 0.2 mm. The other parameters were determined after the calibration. The infill ratios of FDM were determined by the calculated mean HU values of the soft tissue and the lung using the correlation curve between the HU and the infill ratio.

To create the correlation curve, 10 rectangular samples (width × length × height = 40 mm × 40 mm × 20 mm) were created by varying infill ratios from 10% to 100%. The infill ratios ranged from 0% to 100%, which is the ratio of the volume of a printed thermoplastic to that of air. The samples were printed in a grid pattern using PLA material and the FDM method, which were fabricated by varying the infill ratio by 10%. In total 10 samples, with infill values ranging from 10% to 100%, were scanned to a thickness of 1 mm using a Siemens SOMATOM Definition AS CT Scanner (Siemens Healthcare, Erlangen, Germany), at a voltage of 120 kV and current of 10 mA. All HU measurements, such as the maximum, minimum, and mean, were obtained using an ROI of 30 mm × 34 mm × 15 mm on the scanned CT image. **Figure 2** shows the linear relationship between the infill value (%) and HU as the infill ratios of the 3D printer were increased from 10% to 100% in increments of 10 percentage points. For the linear trend line, we derived an equation of \( y = 11.438x - 1,005.9 \), where the \( R^2 \) value was 0.997. As a result, the HU was obtained by varying the infill ratios from 10% to 100%, thereby changing the average HU from −882 to 148.
The FDM lung model and the soft tissue model were fabricated by applying infill ratios corresponding to the calculated mean HU values. We then assembled the two models into one. The 3D-printed water-equivalent phantom was also fabricated to reflect an infill ratio corresponding to 0 HU to verify the vendor-provided depth dose curve. As shown in Figure 3, the water-equivalent phantom was sectioned into upper and lower parts, including a space for the spherical applicator. A piece of EBT3 film was placed between separate parts perpendicular to the spherical applicator.

Gafchromic EBT3 Film Calibration

A Gafchromic EBT3 film was used for dose measurement by using patient-specific 3D chest phantoms. The EBT3 film consisted of a 28-μm-thick active layer and 125-μm-thick protective layers covering the active layer. Scanning the film before and after irradiation and measuring its optical density allowed us to measure the dose delivered to the film. The optical density of the exposed film was converted into a dose via the dose calibration curve.

Dose calibration was performed using a parallel-plate ionization chamber (PTW 23342, Germany) and the EBT3 film on the same INTRABEAM™ system through a conventional technique (20), with exposures ranging from 0 to 20 Gy. The ionization chamber was positioned on the surface of the EasyCube® phantom (Sun Nuclear Corporation, FL, USA), which consisted of water-equivalent slabs of different dimensions and a customized housing holder. The dimensions of the phantom were 16 cm × 16 cm × 8 cm, as shown in Figure 4. The absolute dose outputs within the range of doses of interest were measured to determine the durations of treatment in terms of absorbed doses on the phantom surface in contact with the spherical applicator (with a diameter of 35 mm). Each piece of the EBT3 film placed on the surface of the phantom was exposed to nine absorbed doses (0, 0.2, 0.5, 1, 2, 5, 10, 15, and 20 Gy) to cover the full dynamic range of the film. All measurements of the film were performed twice to verify the reproducibility of the results.

The exposed EBT3 films were digitized using the commercially available Vidar Dosimetry Pro Advantage Red digitizer. The results were analyzed using the RIT version 6.1 software package (RIT, Denver, CO, USA). Uniform ROIs corresponding to the center of each film (10×10 mm² subsets) were chosen for 16-bit red channel calibration. A third-degree polynomial function was used to fit the calibration curve of the film, as shown in Figure 5.

To obtain precise and reproducible film dosimetry results, the films were scanned over the same period (24 h irradiation-to-
scanning time) after irradiation had been performed at the same orientation because process consistency is crucial to reducing potential uncertainties.

**Measurements and Data Analysis**

The Institutional Review Board of the Gangnam Severance Hospital, Korea (IRB No. 3-2017-0033), approved this prospective study in accordance with ethical guidelines and the Declaration of Helsinki.

All measurements were carried out in the 3D-printed water-equivalent phantom as well as the patient-specific 3D chest phantoms created based on five patients receiving IORT. In the water-equivalent phantom, a piece of EBT3 film was exposed parallel to the axis of the beam by placing it along the border of the space for the spherical applicator and between the upper and lower parts of the phantom. This made it possible to bring one side of the film in direct contact with the applicator. The depth dose measured using the film was compared with the depth dose curve provided by the supplier.

For the patient-specific 3D chest phantoms, the piece of EBT3 film was placed on a horizontal plane perpendicular to the axis of the radiation beam. The central region of the piece of film was in direct contact with the surface of the spherical applicator, which had a diameter of 35 mm. The other piece of the film was inserted between separate parts of the phantom in a vertical plane parallel to the axis of the radiation beam (Figure 6). The treatment duration was calculated such that a 10 Gy dose was delivered on the surface of the applicator.

All exposed films were processed to quantify the dose distributions via the dose calibration curve using RIT. A 5 × 5 median filter was applied to each film, and random outliers were excluded from the analysis. The point dose measured from the film placed on the horizontal plane was determined via the maximum value extracted from the dose histogram of each irradiated film. Depth dose curves were acquired at depths from 0 to 30 mm through the profile of a piece of film placed on the vertical plane.

**RESULTS**

**Evaluations With a 3D-Printed Water-Equivalent Phantom**

For precise dosimetric examination, it is necessary to ensure that the 3D-printed density matches the preset density of the infill (14). A CT scan of the 3D-printed water-equivalent phantom was performed to calculate the actual density by comparing it with values in an image value-to-density table. The 3D-printed water-equivalent phantom exhibited a mean of 7 ± 59 HU, in the range from −190 HU to 195 HU. The actual average density was 1.003 g/cm³. Table 1 shows the differences in dose at each depth, between data provided by the vendor and those obtained from the EBT3 film parallel to the axis of the beam, obtained using the 3D-printed water-equivalent phantom. The average of three measurements was reported as the representative estimate, and its estimated uncertainty was based on the absolute value of the difference between each measurement and the average value. The average difference between the vendor and EBT3 film data was
18.3 ± 24.9 cGy (1.8% ± 2.5%), with a difference of up to 64.3 cGy (6.4%) found at a depth of 5 mm. The mean uncertainty in the EBT3 measurement was 16.8 cGy (a maximum of 83.9 cGy at a depth of 0 mm). The measured dose was underestimated at a depth of 0 mm, which corresponded to the border of the piece of film; specifically, this underestimation occurred because of increased uncertainty due to the damage caused by cutting the EBT3 film into pieces. As the depth increased beyond 5 mm, the uncertainty in the measurements performed using the EBT3 film decreased, and a good agreement in terms of absolute dose was obtained between the EBT3 film and the vendor data.

Evaluations With 3D-Printed Patient-Specific Chest Phantoms

Chest phantoms of five patients were fabricated for PSQA measurements. IORT patients were randomly selected and the applicator was used for PSQA measurements. Table 2 shows the location of the dose measurement for each patient and the distance between the tumor and the lung. The mean and standard deviation of the HU values of the voxels inside each ROI (soft tissue and lung) were calculated. Based on an infill ratio corresponding to the mean HU value, the customized chest phantoms were fabricated using the 3D printer, as shown in Figure 7. The 3D-printed soft tissue and lung were sectioned in four and two parts, respectively, to facilitate the reproducible positioning of the spherical applicator and pieces of film. Table 3 shows the HU values of the soft tissue and the lung parts for the five patient-specific 3D chest phantoms. On average, differences in the HU between the patient and the phantom were 2.2 HU for soft tissue and −26.2 HU for the lung. This was in close agreement with the expected HU in terms of the calculated doses. Because each part was printed sequentially, it took 19~50 h to fabricate a single phantom depending on the amount of filament used.

| Depth [mm] | Measured dose (cGy) | Vender-provided depth dose (cGy) | Dose difference (cGy) | Percent error (%) |
|-----------|---------------------|--------------------------------|----------------------|------------------|
|           | 1st trial | 2nd trial | 3rd trial | Mean ± stddev. |                 |                     |                      |                  |
| 0         | 1037.2    | 939.9     | 1,083.8  | 987.0 ± 83.9   | 1,000            | −13.0               | −1.3                |                  |
| 5         | 493.8     | 514.9     | 528.3    | 512.3 ± 17.4   | 448              | 64.3                | 6.4                 |                  |
| 10        | 271.3     | 281.9     | 280.9    | 278.0 ± 5.8    | 242              | 36.0                | 3.6                 |                  |
| 15        | 158.9     | 154.1     | 161.3    | 158.1 ± 3.6    | 145              | 13.1                | 1.3                 |                  |
| 20        | 100.8     | 95.6      | 98.4     | 98.2 ± 2.6     | 93               | 5.2                 | 0.5                 |                  |
| 25        | 74.9      | 70.8      | 73.1     | 72.9 ± 2.1     | 63               | 9.9                 | 1.0                 |                  |
| 30        | 58.5      | 54.5      | 56.9     | 56.6 ± 2.0     | 44               | 12.6                | 1.3                 |                  |

Percent error (%) = dose difference/prescription dose × 100%.

| Patient no. | Site       | Distance between the tumor and the lung | HU of patient CT (mean ± st. dev.) |
|-------------|------------|----------------------------------------|------------------------------------|
| Patient 1   | Left upper | ≤1 cm                                  | −60 ± 53 HU                         | −582 ± 182 HU                     |
| Patient 2   | Left upper | ≤1 cm                                  | −38 ± 52 HU                         | −805 ± 158 HU                     |
| Patient 3   | Right upper| >1 cm                                  | −44 ± 55 HU                         | −725 ± 140 HU                     |
| Patient 4   | Left lower | >1 cm                                  | −61 ± 53 HU                         | −803 ± 153 HU                     |
| Patient 5   | Right lower| ≤1 cm                                  | −37 ± 59 HU                         | −713 ± 162 HU                     |
used. The weight of the filament used ranged from 329 g to 975 g. The 3D printing process required only approximately 30 min of labor to fill, clean, assemble, and verify the printed phantom. The infill ratio of printing ranged from 83% to 85% for soft tissue and 18% to 37% for the lung. The Dice similarity coefficient (DSC) was considered to quantify the similarity between the corresponding structures. The DSC ranges from 0 (no overlap) to 1 (perfect overlap). A large DSC value indicates good overlap between the 3D-printed phantom and the patient. As shown in Figure 8, CT images of the patients and those of their corresponding phantoms

TABLE 3 | Printing information, HU, HU difference, and Dice similarity coefficient (DSC) for the five patient-specific 3D chest phantoms fabricated by using a 3D printer.

|                  | PSQA 1          | PSQA 2          | PSQA 3          | PSQA 4          | PSQA 5          |
|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Printing time    | 2,994 min.      | 1,147 min.      | 3,014 min.      | 1,441 min.      | 1,731 min.      |
| (soft tissue + lung) | 615 g         | 329 g         | 975 g         | 404 g         | 452 g         |
| HU of phantom CT (mean ± st. dev.) |                |                |                |                |                |
| Soft tissue      | −48 ± 29 HU     | −42 ± 29 HU     | −49 ± 92 HU     | −56 ± 74 HU     | −56 ± 83 HU     |
| Lung             | −580 ± 96 HU    | −793 ± 154 HU   | −680 ± 124 HU   | −762 ± 184 HU   | −705 ± 172 HU   |
| HU Difference between patient CT and phantom CT |                |                |                |                |                |
| Soft tissue      | −12             | 4              | 5              | −5             | 19             |
| Lung             | −2              | −7             | −45            | −41            | −8             |
| DSC between patient CT and phantom CT |                |                |                |                |                |
| Soft tissue      | 0.97            | 0.97           | 0.97           | 0.98           | 0.97           |
| Lung             | 0.97            | 0.98           | 0.97           | 0.96           | 0.97           |
were visually matched and then fused to calculate the DSC in the soft tissue and the lung, respectively. On average, the DSC between the patient and the phantom was 0.97 for the soft tissue and 0.97 for the lung.

Table 4 shows the differences between the 1,000 cGy dose administered on the surface of the 35-mm spherical applicator and the dose measured from the pieces of film perpendicular to the axis of the beam. The film measurements ranged from 930.2 cGy to 1,025.6 cGy for the five patient-specific chest phantoms. An evaluation of these measurements versus the prescribed dose indicates that the mean dose difference was $-21.6 \pm 39.1$ cGy, and the mean percentage error was $-2.16\% \pm 3.91\%$.

Figure 9 shows the depth dose measurements of the five PSQA phantoms using pieces of film parallel to the axis of the beam. The measured dose at shallow depths along the border of the film had been underestimated. A depth of 2 to 3 mm was found to be adequate to initiate the depth dose curve. This implies that the first few millimeters along the border of the film could not be used when performing parallel film measurements because the EBT3 film was cut into pieces. This finding is consistent with those of previous studies (21, 22), which have reported damage to the film pieces. Unlike megavoltage-scale X-rays, kilovoltage-scale depth dose curves produced by INTRABEAM™ led to a steep fall-off in the dosage with depth. This is beneficial to the organs at risk in the environment of the lesion and allows radiation oncologists to prescribe higher doses to the lesion itself.

**DISCUSSION**

Few studies have examined PSQA for IORT. This subject is of particular concern in the context of single-session radiotherapy techniques such as IORT where there is no opportunity to compensate for possible errors in later treatment sessions. In light of this, this study developed a simple and non-toxic PSQA method for IORT using 3D printing. The results confirm the feasibility of PSQA for IORT using a 3D printer and a conventionally used PLA filament to fabricate a patient-specific chest phantom. FDM printers are the most economical 3D printers, and they will be advantageous for future clinical applications. In this study, only one FDM-type 3D printer was used to fabricate the patient-specific chest phantoms. The fabricated phantoms can be evaluated in terms of the lung ($-803$ to $-582$ HU) and soft tissue ($-61$ to $-37$ HU), which have a lower physical density than water, by changing the infill ratio. Although differences in HU values between the patients and the phantoms were observed (the $\Delta$HU of soft tissue =

---

**Table 4** | Comparison between the measured dose from the EBT3 film placed on the horizontal plane perpendicular to the beam axis and the prescription dose using five patient-specific chest phantoms.

| No. | Prescription dose (cGy) | Measured dose (cGy) | Measured dose – prescription dose (cGy) | Percent error (%) |
|-----|-------------------------|--------------------|----------------------------------------|------------------|
| PSQA 1 | 1,000 | 992.2 | $-7.8$ | $-0.78$ |
| PSQA 2 | 1,000 | 930.2 | $-69.8$ | $-6.98$ |
| PSQA 3 | 1,000 | 997.5 | $-2.5$ | $-0.25$ |
| PSQA 4 | 1,000 | 946.5 | $-53.5$ | $-5.35$ |
| PSQA 5 | 1,000 | 1025.6 | 25.6 | 2.56 |

---

**Figure 8** | Image fusion between the patient’s CT and the 3D-printed phantom CT.

**Figure 9** | Depth doses measured from the EBT3 film parallel to the beam axis using the five 3D chest phantoms on the INTRABEAM™ system using a 35 mm spherical applicator.
the experiment used only five cases, as printing individual phantoms is time and resource intensive. On average, a single phantom fabrication took 35 h. This 3D printing process might not be practical for general PSQA. However, given the rapid pace of development of 3D printing at present, these technologies are expected to improve dramatically over the next few years to provide better convenience, speed, and precision. Third, standard printing procedures should be used to ensure consistency. Special caution should be taken regarding the first layer of each print, as distortion can be caused by the material not completely sticking to the print bed.

Our study has some limitations. First, the PSQA phantom fabrication described in this study may not adequately reproduce all the uncertainties arising in clinical settings. In the breast IORT procedure, a spherical applicator is placed inside the tumor cavity, then the wall of the tumor cavity is pulled firmly to the applicator surface using a purse-string suture. This process can lead to soft tissue compression due to pre-fixation pressure as well as potential air gaps near the applicator surface in some areas of the breast. Additionally, contrary to our study assuming that the position of the applicator in the intercostal space excludes bone-equivalent heterogeneity in the phantom, in some cases during this fixation process the position of the applicator may be on the ribs. In this case, there may be a significant dose in the ribs. Second, skin and subcutaneous tissue doses are a significant problem with breast IORT. In our study, skin measurements were not taken into account in the PSQA phantom because an optically stimulated luminescence dosimeter was clinically used for in vivo dosimetry to detect radiation doses delivered to the skin during breast IORT (28). However, the most common late toxicity, with a maximum appearance four years following treatment, is telangiectasia. The development of telangiectasia is strongly correlated with the doses applied to the subcutaneous vessels. Measuring the skin dose on the PSQA phantom can help prevent the onset of severe telangiectasia after several years. Therefore, PSQA phantom development must incorporate this skin measurement prior to patient treatment; this leads to a more secure treatment through personalized pretreatment dosimetry investigations. Nevertheless, owing to the absence of sufficient QA data regarding IORT, our method for creating a simplified phantom composed of soft tissue and lung models could be an important milestone in mimicking personalized dosimetry.

**CONCLUSIONS**

In this study, patient-specific 3D-printed chest phantoms were successfully constructed to simulate the IORT-related dose distributions to cancerous tumors, surgical tumor bed, and the surrounding low-density organs such as lungs and soft tissue. This allows not only for the prediction of the depth dose at various distances from the spherical applicator, but also for the verification of the dose by comparing the prescribed dose to the expected dose. The proposed 3D printing methodology provides a viable and inexpensive method for fabricating variable-density...
solid phantoms for breast IORT-specific PSQA. This enhanced precision offers new opportunities for advancing IORT.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Institutional Review Board of the Gangnam Severance Hospital, Korea (IRB No. 3-2017-0033), in accordance with ethical guidelines and the Declaration of Helsinki. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

1. Dutta SW, Showalter SL, Showalter TN, Libby B, Trifiletti DM. Intraoperative radiation therapy for breast cancer patients: current perspectives. Breast Cancer:Targets Ther (2017) 9:257. doi: 10.2147/BCTT.S112516
2. Chua BH, Henderson MA, Milner AD. Intraoperative radiotherapy in women with early breast cancer treated by breast-conserving therapy. ANZ J Surg (2011) 81(1-2):65–9. doi: 10.1111/j.1445-2197.2010.05431.x
3. Harris EE, Small W. Intraoperative radiotherapy for breast cancer. Front Oncol (2017) 7:317. doi: 10.3389/fonc.2017.00317
4. Liu Q, Schneider F, Ma L, Wenz F, Herskind C. Relative Biologic Effectiveness (RBE) of 50 kV X-rays measured in a phantom for intraoperative tumor-bed irradiation. Int J Radiat Oncol Biol Phys (2013) 85(4):1127–33. doi: 10.1016/j.ijrobp.2012.08.005
5. Vaidya JS, Bulsara M, Baum M, Wenz F, Massarat S, Pigorsch S, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ (2020) 370. doi: 10.1136/bmj.m2836
6. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet (2010) 376(9735):91–102. doi: 10.1016/S0140-6736(10)60837-9
7. Vaidya JS, Bulsara M, Saunders C, Flyger H, Tobias JS, Corica T, et al. Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Brain Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer. JAMA Oncol (2020), e200249–e. doi: 10.1001/jamaoncol.2020.0249
8. Trifiletti DM, Jones R, Showalter SL, Libby BB, Brenin DR, Schroen A, et al. Techniques for intraoperative radiation therapy for early-stage breast carcinoma. Future Oncol (2015) 11(7):1047–58. doi: 10.2217/fon.15.26
9. Hensley FW. Present state and issues in IORT physics. J Radiat Oncol Biol Phys (2017) 12(1):37. doi: 10.1016/j.ijrobp.2016.07.007
10. Eaton D. Quality assurance and independent dosimetry for an intraoperative x-ray device. Med Phys (2012) 39(11):6908–20. doi: 10.1118/1.4761865
11. Tino R, Yeo A, Leary M, Brandt M, Kron T. A systematic review on 3D printed imaging and dosimetry phantoms in radiation therapy. Technol Cancer Res Treat (2019) 18:1533033819870208. doi: 10.1177/1533033819870208
12. Yoon K, Jeong C, Kim S-W, Cho B, Kwak J, Kim SS, et al. Dosimetric evaluation of respiratory gated volumetric modulated arc therapy for lung stereotactic body radiation therapy using 3D printing technology. PloS One (2018) 13(12):e0208685. doi: 10.1371/journal.pone.0208685
13. Ju SG, Kim MK, Hong C-S, Kim JS, Han Y, Choi DH, et al. New technique for developing a proton range compensator with use of a 3-dimensional printer. Int J Radiat Oncol Biol Phys (2014) 88(2):453–8. doi: 10.1016/j.ijrobp.2013.10.024
14. Lee H, Yoon J, Park K, Rim CH, Chung MJ, Seong J. Dose perturbation by metallic biliary stent in external beam radiotherapy of pancreato-biliary cancers. Australas Phys Eng Sci Med (2019) 42(3):745–56. doi: 10.1007/s13246-019-00774-1
15. Skinner L, Fahimian BP, Yu AS. Tungsten filled 3D printed field shaping devices for electron beam radiation therapy. PloS One (2019) 14(6):e0217757. doi: 10.1371/journal.pone.0217757
16. Diamantopoulos S, Kagkiouzis I, Patatoukas G, Kypraiou E, Kouloulias V, Efstathopoulos E, et al. Three dimensional printed electron beam modifier for total skin electron treatments. Med Dosim (2019) 44(2):173–8. doi: 10.1016/j.meddos.2018.05.002
17. Kim M-J, Lee S-R, Lee M-Y, Sohn JW, Yun HG, Choi JY, et al. Characterization of 3D printing techniques: Toward patient specific quality assurance spine-shaped phantom for stereotactic body radiation therapy. PloS One (2017) 12(5):e0176227. doi: 10.1371/journal.pone.0176227
18. Shaikh MY, Burmeister J, Scott R, Kumaraswamy LK, Nalichowski A, Joiner MC. Dosimetric evaluation of incorporating the revised V4.0 calibration protocol for breast intraoperative radiotherapy with the INTRABEAM system. J Appl Clin Med Phys (2020) 21(2):50–9. doi: 10.1002/acm.212807
19. CZM A. Intra-Beam water phantom—instructions for use. G-30-1767-en Version 5.0.
20. Niroomand-Rad A, Blackwell CR, Coursey BM, Gall KP, Galvin JM, McLaughlin WL, et al. Radiochromic film dosimetry: recommendations of AAPM radiation therapy committee task group 55. Med Phys (1998) 25(11):2093–115. doi: 10.1118/l5.398407
21. Steinbeke F, Gevaert T, Tourmel K, Engels B, Verellens D, Storme G, et al. Quality assurance of a 50-kV radiotherapy unit using EBT3 GaChromatic film: a feasibility study. Technol Cancer Res Treat (2016) 15(1):163–70. doi: 10.1177/1533034614565910
22. Fletcher CL, Mills JA. An assessment of GaChromatic film for measuring 50 kV and 100 kV percentage depth dose curves. Phys Med Biol (2008) 53(11):N209. doi: 10.1088/0031-9155/53/11/N209
23. Davis AT, Palmer AL, Nisbet A. Can CT scan protocols used for radiotherapy treatment planning be adjusted to optimize image quality and patient dose? A

**AUTHOR CONTRIBUTIONS**

The data collection, conception, design, and drafting of the manuscript were performed by YHC and HL. The data analysis and interpretation were performed by HL, KP, and IJL. The final manuscript was edited by IJL. Patient enrollment were performed by YAC, JWK, KRP, and IJL, who also contributed to useful discussions on the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education (2019R1I1A1A01062157), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI19C1330).
systematic review. Br J Radiol (2017) 90(1076):20160406. doi: 10.1259/bjr.20160406
24. Eaton D, Duck S. Dosimetry measurements with an intra-operative x-ray device. Phys Med Biol (2010) 55(12):N359. doi: 10.1088/0031-9155/55/12/N02
25. Yasuda T, Beatty J, Biggs P, Gall K. Two-dimensional dose distribution of a miniature x-ray device for stereotactic radiosurgery. Med Phys (1998) 25(7):1212–6. doi: 10.1118/1.598298
26. Beaulieu A, Linden AZ, Phillips J, Arroyo LG, Koenig J, Monteith G. Various 3D printed materials mimic bone ultrasonographically: 3D printed models of the equine cervical articular process joints as a simulator for ultrasound guided intra-articular injections. PloS One (2019) 14(8):e0220332. doi: 10.1371/journal.pone.0220332
27. Kim GB, Lee S, Kim H, Yang DH, Kim Y-H, Kyung YS, et al. Three-dimensional printing: basic principles and applications in medicine and radiology. Korean J Radiol (2016) 17(2):182–97. doi: 10.3348/kjr.2016.17.2.182
28. Lee JJB, Choi J, Ahn SG, Jeong J, Lee HJ, Park K, et al. In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost. Radiat Oncol J (2017) 35(2):121. doi: 10.3857/roj.2017.00150

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.